3-(2-hydroxyethoxy)dihydrofuran-2-one | 1333401-27-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: 3-(2-hydroxyethoxy)dihydrofuran-2-one
• 英文别名: 3-(2-Hydroxyethoxy)dihydrofuran-2(3H)-one；3-(2-hydroxyethoxy)oxolan-2-one
• CAS: 1333401-27-6
• 化学式: C₆H₁₀O₄
• 分子量: 146.143
• InChiKey: ITFPVXFWLJYGQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-(2-benzyloxy-ethoxy)-tetrahydro-furan-2-ol 在 palladium on activated charcoal 氢气 、 乙酸酐 、 二甲基亚砜 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 20.0h， 生成 3-(2-hydroxyethoxy)dihydrofuran-2-one
  参考文献：
  名称：

  [EN] HETEROCYCLIC AMIDES AS ROCK INHIBITORS
  [FR] AMIDES HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE ROCK

  摘要：

  公开号：

  WO2011107608A8

文献信息

• NOVEL AROMATIC COMPOUND AND USE THEREOF
  申请人：Kyoto Pharmaceutical Industries, Ltd.

  公开号：US20160207883A1

  公开（公告）日：2016-07-21

  Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.

  提供的是一种显示促进骨形成作用（和/或抑制骨吸收作用）的化合物。具有以下结构的化合物（I）或药理学上可接受的盐：[其中每个取代基如描述中所定义]，具有低毒性，显示良好的药代动力学特性，具有促进骨形成的作用，并且对于预防或治疗代谢性骨疾病（骨质疏松症、纤维性骨炎（甲状旁腺功能亢进症）、软骨软化症、帕吉特病等影响全身骨代谢参数的疾病）非常有用，这些疾病与骨形成能力下降相比骨吸收能力。
• HETEROCYCLIC AMIDES AS ROCK INHIBITORS
  申请人：Leysen Dirk

  公开号：US20120322801A1

  公开（公告）日：2012-12-20

  The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.

  本发明涉及新的激酶抑制剂，更具体地说是ROCK抑制剂，包括这些抑制剂的组合物，特别是制药用途的组合物，并且涉及使用这些抑制剂在治疗和预防疾病方面的用途。特别是，本发明涉及新的ROCK抑制剂，包括这些抑制剂的组合物，特别是制药用途的组合物，并且涉及使用这些抑制剂在治疗和预防疾病方面的用途。此外，本发明还涉及治疗和使用所述化合物制造药物的方法，应用于多种治疗适应症，包括性功能障碍、炎症性疾病、眼科疾病和呼吸系统疾病。
• NOVEL ROCK INHIBITORS
  申请人：Amakem NV

  公开号：US20130252975A1

  公开（公告）日：2013-09-26

  The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.

  本发明涉及新的激酶抑制剂，更具体地，是ROCK抑制剂，包括这种抑制剂的组合物，特别是制药组合物，并且涉及这种抑制剂在治疗和预防疾病方面的用途。特别地，本发明涉及新的ROCK抑制剂，包括这种抑制剂的组合物，特别是制药组合物，并且涉及这种抑制剂在治疗和预防疾病方面的用途。此外，本发明还涉及使用该化合物的治疗方法和制造药物的用途，适用于多种治疗适应症，包括性功能障碍、炎症性疾病、眼科疾病和呼吸系统疾病。
• Heterocyclic amides as rock inhibitors
  申请人：Amakem NV

  公开号：EP2626348A1

  公开（公告）日：2013-08-14

  The present invention relates to new kinase inhibitors of general formula IIaa, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including ophthalmic diseases.

  本发明涉及通式IIaa的新激酶抑制剂，更具体地说，涉及ROCK抑制剂、包含此类抑制剂的组合物，特别是药物，以及此类抑制剂在治疗和预防疾病中的用途。特别是，本发明涉及新的 ROCK 抑制剂、包含这种抑制剂的组合物，尤其是药物，以及这种抑制剂在治疗和预防疾病中的用途。 此外，本发明还涉及上述化合物的治疗方法和在制造药物中的用途，以应用于包括眼科疾病在内的多种治疗适应症。
• Aromatic compound and use thereof
  申请人：Kyoto Pharmaceutical Industries, Ltd.

  公开号：US10059663B2

  公开（公告）日：2018-08-28

  Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.

  本文提供了一种具有促进骨形成作用（和/或抑制骨吸收作用）的化合物。式（I）的化合物或药理学上可接受的盐： [其中各取代基如 DESCRIPTION 所定义]，毒性低，药代动力学良好，具有促进骨形成的作用，可用于预防或治疗与骨形成能力低于骨吸收能力相关的代谢性骨病（骨质疏松症、纤维性骨炎（甲状旁腺功能亢进）、骨软化症、影响全身骨代谢参数的 Paget 病等）。